Clinical Trial Update: A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations [Phase 2]

View source ↗

Summary

A Phase II nationwide, fully decentralized telemedicine study of pemigatinib for adults with FGFR-altered advanced or metastatic pancreatic cancer is currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Pemazyre (pemigatinib)

Snippet

Sponsor: Sameek Roychowdhury | Conditions: Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma | Phase 2 | Status: RECRUITING